SNMMI's communications staff is available to handle your inquiries, arrange interviews with experts, provide copies of research articles and more.
For assistance, please contact Susan Martonik, associate director of public relations, at email@example.com or at (703) 652-6773.
SNMMI is dedicated to being the premier source of information on nuclear medicine and molecular imaging. SNMMI's online newsroom provides reporters with the information needed to write articles and gain background information on the many topics related to molecular imaging and therapy and nuclear medicine.
SNMMI issues press releases on new research, society updates and industry news for members of the press. Check back frequently to see what's new with SNMMI.
View press releases on the latest research and news from SNMMI.
Nuclear and molecular imaging are vital elements of today's medical practice, adding an additional dimension to diagnosis that can change the way diseases are understood and treated. Nuclear medicine therapies treat specific diseases, such as lymphoma or thyroid cancer, by allowing a high dose of medicine to be delivered directly to a tumor or problem area. SNMMI's fact sheets explain how nuclear medicine and molecular imaging can help diagnose and/or treat a wide range of diseases.
SNMMI publishes two peer-reviewed medical journals—The Journal of Nuclear Medicine (JNM) and The Journal of Nuclear Medicine Technology (JNMT)—which feature the latest in molecular imaging research. JNM and JNMT are the most widely read peer-reviewed publications in molecular imaging, nuclear medicine and allied disciplines.
Every month, JNM brings readers around the globe clinical investigations, basic science reports, continuing education articles, book reviews, employment opportunities, and updates on rapidly changing issues in practice and research. JNM's Newsline offers in-depth reporting on news affecting every facet of the field—the latest scientific events, government decisions, industry developments, socio-economic trends, and a broad selection of reviews from the literature.
Published quarterly, JNMT focuses on technology, quality assurance, radiation safety, and the clinical applications of nuclear medicine. Each issue features continuing education articles written by leading educators in nuclear medicine technology as well as news and updates on practice, licensure, and credentialing for nuclear medicine technologists. Practitioners from across the imaging sciences turn to JNMT for peer-reviewed information related to daily clinical practice.
SNMMI can connect you with subject-matter experts on a variety of topics who are ready to respond to tight deadlines. Contact Susan Martonik, SNMMI's associate director of public relations, at firstname.lastname@example.org or at (703) 652-6773, to set up an interview with SNMMI's leadership or with one of its many experts on oncology, brain disease, heart disease, radiopharmaceuticals, reimbursement and more.
Join SNMMI on our social media networks to stay updated on the latest from the society and the nuclear medicine and molecular imaging field.
Typical Alzheimer’s neuroimaging looks at amyloid deposition and neurofibrillary tangles, but a new quantitative method uses arterial input to bring signs of functional disease into sharper relief, according to a study published April 16 in the Journal of Nuclear Medicine .
(MI: Making a Difference)
As many of you know, a drastic price increase for macroaggregated albumin (MAA) went into effect on April 1. With all the anger, misstatements and misinformation circulating within the community, I wanted to share with you the SNMMI Board of Directors’ deliberations on this serious issue, as well as discussions we have held with Jubilant Draxlmage (JDI), the sole provider of this product.
In September of 2013, CMS issued its final decision memo that concluded positron emission tomography- amyloid beta (PET Aß) imaging is “not reasonable or necessary”, finding “insufficient evidence” that use of this diagnostic tool would improve health outcomes for patients with dementia or neurodegenerative disease. As such, PET Aß imaging to help diagnose Alzheimer’s disease (AD) is not a covered service for Medicare beneficiaries except for those enrolled in CMS-approved clinical trials.
(SNMMI in the News)
Positron emission mammography was found to have 100 sensitivity for all imaged breast tumors, according to a study being presented during the 2014 European Congress of Radiology scientific sessions.
(MI: Making a Difference)
Tools, supported by evidence, to harmonize the practice of nuclear medicine using a progressive and safe approach.
Learn more about journals published by or sponsored by the Society of Nuclear Medicine and Molecular Imaging.